Rosiglitazone
Top View
- Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer
- Product Monograph
- Clinical Review Hyon Kwon, Pharmd, MPH Snda 208751/S-010 and S-011 Fiasp (Insulin Aspart)
- Dual Pparα/Γ Activation Inhibits SIRT1-Pgc1α Axis and Causes Cardiac Dysfunction
- Insulin Overview
- Over 10 Years After the Diabetes Drug Rosiglitazone Was Approved by Regulators, and Despite Studies on Tens of Thousands Of
- An Endogenous Peroxisome Proliferator-Activated Receptor ␥ Ligand
- Specific Inhibition of the Distribution of Lobeglitazone to the Liver
- EGFR Signaling and the Anti- Cancer Effects of Thiazolinedinediones Jesse Roman1
- A Novel Pparγ Agonist, SP1818, Shows Different Coactivator Profile with Rosiglitazone
- The Effect of Antidiabetic Medications on Non-Alcoholic Fatty Liver Disease
- Comparison of Insulin Degludec/Insulin
- Rosiglitazone Suppresses Human Lung Carcinoma Cell Growth Through PPAR;-Dependent and PPAR;-Independent Signal Pathways
- Elucidation of Molecular Mechanism of a Selective PPAR Modulator
- Avandia Label
- Insulin Overview
- Insulin Degludec/Insulin Aspart (Degludecplus) for Type 2 Diabetes
- Insulin Lispro | Memorial Sloan Kettering Cancer Center